Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Amortizatization of Intangibles (2017 - 2025)

Historic Amortizatization of Intangibles for Denali Therapeutics (DNLI) over the last 9 years, with Q3 2025 value amounting to $900000.0.

  • Denali Therapeutics' Amortizatization of Intangibles rose 12500.0% to $900000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.5 million, marking a year-over-year increase of 76725.0%. This contributed to the annual value of $1.2 million for FY2024, which is N/A changed from last year.
  • As of Q3 2025, Denali Therapeutics' Amortizatization of Intangibles stood at $900000.0, which was up 12500.0% from $900000.0 recorded in Q2 2025.
  • Denali Therapeutics' Amortizatization of Intangibles' 5-year high stood at $11.5 million during Q2 2023, with a 5-year trough of -$2.7 million in Q3 2021.
  • Moreover, its 5-year median value for Amortizatization of Intangibles was $688000.0 (2022), whereas its average is $967133.3.
  • In the last 5 years, Denali Therapeutics' Amortizatization of Intangibles crashed by 552857.14% in 2021 and then soared by 244887.98% in 2023.
  • Quarter analysis of 5 years shows Denali Therapeutics' Amortizatization of Intangibles stood at -$2.4 million in 2021, then skyrocketed by 158.8% to $1.4 million in 2022, then surged by 706.5% to $11.5 million in 2023, then plummeted by 93.33% to $769000.0 in 2024, then increased by 17.04% to $900000.0 in 2025.
  • Its Amortizatization of Intangibles was $900000.0 in Q3 2025, compared to $900000.0 in Q2 2025 and $900000.0 in Q1 2025.